Thiogenesis Therapeutics Corp (TTI) News

Set to begin shortly, Thiogenesis Therapeutics (TTI.v) will be commencing a multi-country, multi-center trial in France and the Netherlands to evaluate the safety, tolerability, and efficacy of its TTI-0102 as a potential treatment for MELAS, a rare mitochondrial disorder with no approved therapies: https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/

Thiogenesis Therapeutics (TTI.v) has received final regulatory clearance from the European Medicines Agency (EMA) to proceed with its Phase 2 clinical trial for TTI-0102, a potential treatment for mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS): https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/

The multi-country, multi-center trial in France and the Netherlands will evaluate the safety, tolerability, and efficacy of oral TTI-0102 in 12 patients over six months, with an interim analysis at three months.

Notably, TTI-0102 is a prodrug designed to increase intracellular glutathione and taurine, addressing key deficiencies in MELAS patients. It improves on earlier thiol-based treatments by offering a longer half-life and fewer side effects. MELAS, a rare mitochondrial disorder affecting 4.4 per 100,000 people, leads to seizures, fatigue, and muscle weakness, with oxidative stress and taurine deficiency as potential treatment targets.

Gearing up for Phase II clinical trials in 2025 for TTI-0102, a next-generation treatment targeting MELAS, Leigh syndrome, and pediatric MASH, Thiogenesis Therapeutics (TTI.v TTIPF) is a unique clinical-stage biotech company focused on devastating diseases with no approved therapies: https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/

With its innovative sustained-release cysteamine prodrug, streamlined FDA approval pathway, and expanding global patents, Thiogenesis is rapidly advancing toward potentially game-changing treatments for mitochondrial and metabolic disorders.

Allowing the company to proceed with its multi-center trial in France and the Netherlands, evaluating the safety, tolerability, and efficacy of TTI-0102 in 12 patients over six months, Thiogenesis Therapeutics (TTI.v) has received final regulatory clearance from the European Medicines Agency (EMA) to initiate its Phase 2 clinical trial: https://x.com/StckMasterFlash/status/1883977520837443663

With no approved treatments for MELAS, TTI-0102 offers a novel approach by boosting intracellular glutathione and taurine, addressing key deficiencies in patients. CEO Patrice Rioux highlighted its potential as a viable therapeutic, overcoming limitations of earlier thiol-based drugs. This approval marks a significant step in advancing a promising treatment for an unmet medical need.

Thiogenesis Therapeutics (TTI.v TTIPF) is working to launch Phase II trials in 2025 for TTI-0102, a drug targeting MELAS, Leigh syndrome, and pediatric MASH, all with significant unmet medical needs. TTI-0102 offers sustained release unlike other cysteamine-based treatments, reducing oxidative stress while improving tolerability and bioavailability. More here: https://thiogenesis.webflow.io/investors

*Posted on behalf of Thiogenesis Therapeutics Corp.

Marking a significant mitigation of risk, Thiogenesis Therapeutics (TTI.v) has received EU clearance to commence its Phase 2 clinical trials for TTI-0102 as a potential treatment for MELAS: https://x.com/StckMasterFlash/status/1883977520837443663
 
Set to begin shortly, the trials are a multi-country, multi-center, randomized, double-blind, placebo-controlled study which will be taking place in France and the Netherlands, assessing the safety, tolerability, pharmacodynamics and efficacy of oral TTI-0102 for the treatment of patients with MELAS, a condition with no current approved drugs.

With the acceptance of the final regulatory clearance from the European Medicines Agency needed to commence its Phase 2 clinical trial for TTI-0102, a potential treatment for MELAS, Thiogenesis Therapeutics (TTI.v) is set to begin shortly: https://x.com/StckMasterFlash/status/1883977520837443663

The multi-country, multi-center, randomized, double-blind, placebo-controlled study will be taking place in France and the Netherlands, assessing the safety, tolerability, pharmacodynamics and efficacy of oral TTI-0102 for the treatment of patients with MELAS, a condition with no current approved drugs.

Today, Thiogenesis Therapeutics (TTI.v) announced that the European Medicines Agency (EMA) has accepted the final regulatory clearance (CTA Part II) needed to commence its Phase 2 clinical trial for TTI-0102, a potential treatment for mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS): https://www.newsfilecorp.com/release/238463/Thiogenesis-Receives-Final-EU-Clearance-of-CTA-to-Initiate-its-Phase-2-Clinical-Trial-in-MELAS

The trial is set to begin shortly, following the activation of clinical trial sites, multi-country, multi-center, randomized, double-blind, placebo-controlled study in France and the Netherlands, assessing the safety, tolerability, pharmacodynamics and efficacy of oral TTI-0102 for the treatment of patients with MELAS. Notably, there are currently no approved drugs for the condition.

Thiogenesis Therapeutics (TTI.v) is a groundbreaking clinical-stage biotech company revolutionizing the treatment of rare mitochondrial dysfunction diseases through its innovative thiol-active compounds: https://x.com/StckMasterFlash/status/1882535523035791823

Its flagship product, TTI-0102, is a prodrug of cysteamine designed to enhance dosing efficiency and minimize side effects that's focused on high-value, rare conditions in a lucrative CAD 9.8 billion global market opportunity.

Advancing its ambitious pipeline with clinical trials for TTI-0102, TTI is set to tackle multiple rare diseases with key milestones including Phase II trials for MELAS and Leigh Syndrome beginning in 2025, with market launches anticipated by 2026-2027 and projected combined peak sales of CAD 4.14 billion.

Thiogenesis Therapeutics (TTI.v) is a clinical-stage biotech company specializing in thiol-active compounds to treat mitochondrial dysfunction diseases. Its lead product, TTI-0102, is a prodrug of cysteamine designed to improve dosing and reduce side effects and, according to Valuation Lab, with a risk-adjusted net present value (NPV) of CAD 7.5 per share, Thiogenesis offers a significant upside of 1130%: https://x.com/StckMasterFlash/status/1871347807430291939

Targeting three rare diseases and conditions with significant unmet medical needs, Thiogenesis Therapeutics (TTI.v) is represents a significant opportunity in addressing both rare diseases and broader oxidative stress-related challenges with its innovative thiol-based drug TTI-0102: https://www.reddit.com/r/wallstreetsmallcaps/comments/1hxs2xe/biotech_thiogenesis_therapeutics_ttiv_advances/

Streamlining development by leveraging expedited regulatory pathways in the US and Europe, TTI is able to significantly reduce costs and time to market in an estimated $9.8 billion market opportunity, strongly positioning the company to address critical gaps in the rare disease and antioxidant therapy space.

Clinical stage biotech company Thiogenesis Therapeutics (TTI.v) and its lead product, innovative thiol-based drug TTI-0102, have significant potential, extending beyond addressing rare conditions—it signifies a broader opportunity to revolutionize therapeutic strategies for oxidative stress-related diseases: https://www.reddit.com/r/wallstreetsmallcaps/comments/1hxs2xe/biotech_thiogenesis_therapeutics_ttiv_advances/

For MELAS, affecting 30,000 individuals in the US, TTI-0102’s ability to mitigate neurological symptoms and stroke-like episodes through mitochondrial support is groundbreaking. In Rett Syndrome, the drug’s promotion of Brain-Derived Neurotrophic Factor (BDNF) could restore nerve cell health and improve motor and cognitive function. Similarly, in pediatric NASH, which impacts 7 million children in the US, TTI-0102’s anti-inflammatory and antioxidant properties offer hope for a condition leading to severe liver complications. With a strong safety profile derived from cysteamine’s pediatric use and a focus on conditions with no existing approved treatments, TTI represents a significant leap forward in addressing both rare diseases and broader oxidative stress-related challenges.

Poised to transform the treatment landscape for rare diseases and conditions with significant unmet medical needs through its innovative thiol-based drug, TTI-0102, Thiogenesis Therapeutics (TTI.v) offers a novel approach to conditions such as MELAS, Rett Syndrome, and pediatric NASH in targeting mitochondrial dysfunction to address the root causes of these diseases, which currently lack approved therapies: https://x.com/StckMasterFlash/status/1880363437781630998

Leveraging expedited regulatory pathways in the US and Europe, TTI can streamline development by referencing existing safety data from similar compounds, significantly reducing costs and time to market. With an estimated $9.8 billion market opportunity, TTI is well-positioned to address critical gaps in the rare disease and antioxidant therapy space and represents a significant leap forward in addressing both rare diseases and broader oxidative stress-related challenges.

Capitalizing on a $9.8 billion market opportunity within the global rare disease and antioxidant therapies space, Thiogenesis Therapeutics (TTI.v) is focused on the development of thiol-based drugs with its lead product TTI-0102: https://www.reddit.com/r/wallstreetsmallcaps/comments/1hxs2xe/biotech_thiogenesis_therapeutics_ttiv_advances/    

TTI-0102 leverages its proven safety profile (from cysteamine's pediatric use) to target critical unmet medical needs in MELAS, Rett Syndrome, and NASH. By addressing mitochondrial dysfunction through innovative mechanisms, Thiogenesis presents a promising therapeutic approach for these challenging conditions.

Thiogenesis Therapeutics (TTI.v) is capitalizing on a $9.8 billion market opportunity within the global rare disease and antioxidant therapies space by focusing on the development of thiol-based drugs. Leveraging unique properties to address oxidative stress and mitochondrial dysfunction, TTI's novel lead product offers targeted solutions for unmet medical needs including rare conditions such as MELAS, Leigh Syndrome, Rett Syndrome, and Pediatric MASH : https://www.reddit.com/r/wallstreetsmallcaps/comments/1hxs2xe/biotech_thiogenesis_therapeutics_ttiv_advances/

Benefitting from strong regulatory incentives for orphan drug development, TTI's lead product strategically targets both niche and broader applications, positioning the company to drive innovation and deliver significant value in a competitive and high-potential therapeutic area.

Addressing oxidative stress and mitochondrial dysfunction, a $9.8B market with significant unmet medical needs, Thiogenesis Therapeutics (TTI.v) is a rising player in the biotech sector with its novel lead product, TTI-0102, a prodrug of cysteamine designed to improve dosing and reduce side effects: https://www.reddit.com/r/wallstreetsmallcaps/comments/1hxs2xe/biotech_thiogenesis_therapeutics_ttiv_advances/

By pioneering a platform centered on thiol-based molecules, Thiogenesis aims to deliver groundbreaking therapies for rare disorders and conditions lacking effective treatments. Adding to their appeal, orphan disease therapies often benefit from faster regulatory approval, lower R&D expenditures, and extended periods of market exclusivity.

Emerging biopharmaceutical company, Thiogenesis Therapeutics (TTI.v), is focused on harnessing the therapeutic potential of sulfur-based compounds to address oxidative stress and mitochondrial dysfunction, both of which are implicated in a wide range of diseases: https://www.reddit.com/r/wallstreetsmallcaps/comments/1hxs2xe/biotech_thiogenesis_therapeutics_ttiv_advances/

With an innovative platform leveraging the unique properties of thiol-based molecules, TTI's core focus is on developing novel treatments for orphan diseases and conditions with significant unmet medical needs, targeting a CAD$9.8B market opportunity. Notably, this focus on orphan diseases offers the potential for expedited regulatory pathways, reduced development costs, and attractive market exclusivity periods.

Targeting a projected global market opportunity of CAD$9.8B, Thiogenesis Therapeutics (TTI.v) is focused on addressing rare conditions including MELAS, Leigh Syndrome, Rett Syndrome, and Pediatric MASH with its lead product, TTI-0102. Poised to make a significant impact on the market, TTI is at the start of a transformational year with multiple trials and regulatory filings expected to provide significant inflection points: https://x.com/StckMasterFlash/status/1877827587096879527

Interested in a unique opportunity in biotech space? Check out Thiogenesis Therapeutics (TTI.v), a clinical-stage company specializing in thiol-active compounds to treat rare mitochondrial dysfunction diseases, targeting an estimated global market of CAD 9.8 billion:  https://x.com/StckMasterFlash/status/1871347807430291939

With its lead product, TTI-0102—a prodrug of cysteamine designed to improve dosing and reduce side effects—Thiogenesis is poised to make a significant impact in treating conditions like MELAS, Leigh Syndrome, Rett Syndrome, and Pediatric MASH. Notably, Valuation Lab estimates a risk-adjusted net present value of CAD 7.5 per share, translating to a staggering 1130% upside. 

Thiogenesis Therapeutics (TTI.v) is advancing a drug which addresses MELAS, Leigh Syndrome, Rett Syndrome, and pediatric MASH, with a global peak sales potential of $9.8B as estimated by a recent Valuation Lab report. Taking into account key upcoming catalysts including phase II trials, Valuation Lab gives TTI a sum-of-parts (r)NPV of $7.50/share, well above its current $0.58 share price. Full report: https://www.valuationlab.com/app/download/8229158562/vL+Thiogenesis+Flash+Update+16DEC24.pdf

*Posted on behalf of Thiogenesis Therapeutics Corp.

Recommend this post on Thiogenesis Therapeutics Corp. (TTI.v TTIPF) and the development of the drug TTI-0102 which is designed to treat pediatric NASH by releasing cysteamine, a potent antioxidant that can reduce oxidative stress and inflammation.

Full post here: https://www.reddit.com/r/Penny_Stocks_Canada/comments/1hwu7ud/thiogenesis_therapeutics_corp_ttiv_ttipf/

*Posted on behalf of Thiogenesis Therapeutics Corp.

Thiogenesis Therapeutics (TTI.v) targets multi-billion dollar markets with its thiol-active compound for mitochondrial dysfunctions, advancing Phase II trials in 2025 for MELAS, Leigh syndrome, and pediatric MASH. Valuation Lab values shares at CAD 7.5, citing strong IP and a cash runway into Q4 2025. Full report here: https://www.valuationlab.com/app/download/8229158562/vL+Thiogenesis+Flash+Update+16DEC24.pdf

*Posted on behalf of Thiogenesis Therapeutics Corp.

Representing a transformative opportunity in the biotech space, Thiogenesis Therapeutics (TTI.v) is leveraging its innovative thiol-based therapeutic platform to address rare and underserved mitochondrial dysfunction diseases: https://x.com/StckMasterFlash/status/1871347807430291939

Unlike most biotech ventures, TTI’s lead candidate, TTI-0102, targets a well-defined niche in conditions such as MELAS, Leigh Syndrome, and Pediatric MASH—areas with significant unmet needs and little market competition. This focus on orphan drug markets positions the company to benefit from expedited regulatory approval pathways and strong pricing power.

Offering a groundbreaking investment opportunity with a projected upside of 1130%, Thiogenesis Therapeutics (TTI.v) is driven by its innovative thiol-active compounds targeting rare mitochondrial dysfunction diseases with its lead product, TTI-0102, addressing significant unmet medical needs in conditions like MELAS, Leigh Syndrome, Rett Syndrome, and Pediatric MASH: https://x.com/StckMasterFlash/status/1871347807430291939

With robust patent protection until 2037, TTI has an ambitious pipeline, featuring Phase II trials and regulatory filings set for 2025, positioning it for market launches by 2026-2027 and potential peak sales exceeding CAD 5.6 billion. TTI's strategic focus on orphan drug markets and licensing for broader indications positions the company to capitalize on expedited regulatory pathways with strong intellectual property, focused strategy, and projected market opportunities making it a compelling read for those seeking high-reward biotech investments.

Good recap of Thiogenesis Therapeutics Corp. (TTI.v TTIPF) and the development of the drug TTI-0102 which is designed to treat pediatric NASH by releasing cysteamine, a potent antioxidant that can reduce oxidative stress and inflammation.

More on Thiogenesis and the addressable market in the post: https://www.reddit.com/r/CanadianStockExchange/comments/1hs6occ/thiogenesis_therapeutics_corp_ttiv_ttipf/

*Posted on behalf of Thiogenesis Therapeutics Corp.

Addressing an estimated global market opportunity of CAD 9.8 billion, Thiogenesis Therapeutics (TTI.v) is a clinical-stage biotech innovating in the treatment of rare mitochondrial diseases, with a focus on high-value orphan indications such as MELAS, Leigh Syndrome, Rett Syndrome, and Pediatric MASH: https://x.com/StckMasterFlash/status/1871347807430291939

At the heart of its pipeline is TTI-0102, a prodrug of cysteamine designed to overcome traditional challenges with dosing and side effects. TTI’s strong intellectual property extending to 2037 and strategic use of expedited regulatory pathways position it as a key player in this niche yet transformative space, offering a compelling high-risk, high-reward opportunity with a risk-adjusted valuation suggesting a potential 1130% upside amid clinical trials beginning in 2025.

Designed to revolutionize the treatment of rare mitochondrial diseases like MELAS and Leigh Syndrome, Thiogenesis Therapeutics (TTI.v), a clinical-stage biotech company, is advancing TTI-0102, a prodrug designed: https://x.com/StckMasterFlash/status/1871347807430291939

Targeting a market opportunity exceeding CAD 9.8 billion, TTI is positioned for a range of key milestones from multiple Phase II trials in 2025, making the company a compelling high-reward investment with an estimated 1130% upside potential, according to Valuation Lab.

Clinical-stage biotech company, Thiogenesis Therapeutics (TTI.v), is advancing TTI-0102, a prodrug designed to revolutionize the treatment of rare mitochondrial diseases like MELAS and Leigh Syndrome: https://x.com/StckMasterFlash/status/1871347807430291939

With patent protection until 2037 and a market opportunity exceeding CAD 9.8 billion, the company is positioned for explosive growth. Key milestones, including multiple Phase II trials in 2025, align with an estimated 1130% upside potential, making TTI.v a compelling high-risk, high-reward investment. If you're intrigued by cutting-edge science, rare disease innovation, and significant financial upside, this report is a must-read.

'A Prodrug for Mito-Dysfunction' Offering 113% Upside Potential - Thiogenesis Therapeutics (TTI.v) Research Report Summary: https://x.com/StckMasterFlash/status/1871347807430291939

Focused on a cutting-edge approach to rare disease treatment with a solid foundation for growth, Thiogenesis Therapeutics (TTI.v) is a clinical-stage biotech company advancing its lead product TTI-0102 to treat rare mitochondrial diseases including MELAS and Leigh Syndrome (LS). TTI offers a high-risk, high-reward investment opportunity, driven by its innovative approach to treating rare mitochondrial diseases and the potential for substantial market penetration across its targeted indications.

Focused on a cutting-edge approach to rare disease treatment with a solid foundation for growth, Thiogenesis Therapeutics (TTI.v) is a clinical-stage biotech company advancing its lead product TTI-0102 to treat rare mitochondrial diseases MELAS and Leigh Syndrome (LS): https://x.com/StckMasterFlash/status/1866620308544786857

MELAS: Phase 2 trial begins in early 2025 (Netherlands & France) targeting 15,000 U.S. and 20,000 EU patients.
Leigh Syndrome: IND filing planned for early 2025 for this severe, untreatable disorder affecting 1 in 40,000 births.

Yesterday, Thiogenesis Therapeutics (TTI.v) presented significant updates on its two clinical programs that are advancing its lead product, TTI-0102 which aims to address oxidative stress and improve outcomes for rare, debilitating conditions that affect a range of patients worldwide: https://x.com/StckMasterFlash/status/1866620308544786857

Having submitted its Clinical Trial Application Part II in Europe, TTI plans to launch a Phase 2 trial in early 2025 in the Netherlands and France for MELAS, focusing on physical endurance and biomarker analysis in 12 patients. For Leigh Syndrome, TTI collaborated with a leading U.S. children’s hospital and engaged in a pre-IND meeting with the FDA, paving the way for an IND submission and a Phase 2a trial in early 2025.

Today, Thiogenesis Therapeutics (TTI.v), a clinical-stage biotechnology company, presented updates on its two clinical programs for mitochondrial diseases during the UMDF "Bench-to-Bedside" webcast: https://www.newsfilecorp.com/release/233143/Thiogenesis-Announces-Presentation-on-UMDF-Webcast-Featuring-Clinical-Trials-in-Mitochondrial-Disease

TTI is advancing its lead product, TTI-0102, with promising applications in treating MELAS, a rare disorder affecting 15,000 patients in the U.S. and 20,000 in the EU, and Leigh Syndrome (LS), which is diagnosed in infancy and affects 1 in 40,000 births (More info: https://www.reddit.com/r/RichTogether/comments/1gvx18y/with_45m_in_the_bank_a_low_burn_rate_strong/)

Last week, clinical-stage biotech company Thiogenesis Therapeutics (TTI.v) announced attaining DTC eligibility in the US, facilitating electronic settlement of its common shares; a significant milestone aligning with the company's plans for a future U.S. listing: https://www.newsfilecorp.com/release/231667/Thiogenesis-Announces-DTC-Eligibility-in-the-U.S.-and-Other-Updates 

Targeting pediatric diseases with unmet medical needs and zero approved drugs or treatments, TTI is focused on developing novel thiol-based compounds to address mitochondrial dysfunction and its related diseases -  a substantial addressable market as mitochondrial diseases collectively affect millions worldwide, with very few effective therapies currently available: https://x.com/StckMasterFlash/status/1859742853578076171

Targeting pediatric diseases with unmet medical needs and zero approved drugs or treatments, Thiogenesis Therapeutics (TTI.v) is a biopharmaceutical company focused on developing novel thiol-based compounds to address mitochondrial dysfunction and its related diseases: https://drive.google.com/file/d/1Obahg9CXnD__6WbReUT93Sgzu6C9EoD_/view

Representing a growing market segment in the pharmaceutical industry, estimates suggest the mitochondrial disease therapies market to be worth USD 1,817 million by 2030. Thus,

By leveraging its innovative compounds and focusing on pediatric diseases with no approved therapies, TTI has the potential to make significant strides in addressing critical gaps alongside addressing multiple indications within this growing market, presenting significant commercial and therapeutic opportunities.

Insightful breakdown of Thiogenesis Therapeutics (TTI.v) and the market opportunity its taking advantage of by focusing on pediatric diseases with unmet medical needs including pediatric NASH which currently has zero approved drugs or treatments: https://x.com/airic101/status/1856816752128143615

Targeting a large addressable market in developing therapeutic compounds for pediatric diseases with unmet medical needs, Thiogenesis Therapeutics (TTI.v) is a clinical-stage biotech company: https://x.com/StckMasterFlash/status/1856131383535542718

Notably, TTI recently announced the approval of its European patent for the treatment of Cysteamine Sensitive Disorders, a medical condition characterized by cellular dysfunction, which complements the companys previous patent approvals in the US and Japan, as well as aligns with TTI's development of TTI-0102, a novel thiol-based prodrug designed to address mitochondrial diseases and related metabolic disorders by enhancing cellular antioxidant defenses.

Developing therapeutic compounds for pediatric diseases with unmet medical needs and a large addressable market, clinical-stage biotech company Thiogenesis Therapeutics (TTI.v), recently announced the approval of its European patent for the treatment of Cysteamine Sensitive Disorders, a medical condition characterized by cellular dysfunction: https://x.com/StckMasterFlash/status/1856131383535542718

Complementing previous patent approvals in the US and Japan, the IP protection aligns with TTI's development of TTI-0102, a novel thiol-based prodrug designed to address mitochondrial diseases and related metabolic disorders by enhancing cellular antioxidant defenses.